Sulfonamides incorporating fluorine and 1,3,5-triazine moieties are effective inhibitors of threeβ-class carbonic anhydrases fromMycobacterium tuberculosis

Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies

(2011) Fabrizio Carta et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium

(2011) Daniela Vullo et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Carbonic anhydrase inhibitors and activators for novel therapeutic applications

(2011) Claudiu T Supuran   Future Medicinal Chemistry

Characterization and inhibition studies of an α-carbonic anhydrase from the endangered sturgeon speciesAcipenser gueldenstaedti

(2011) Sevgi Kolayli et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Interfering with pH regulation in tumours as a therapeutic strategy

(2011) Dario Neri et al.   NATURE REVIEWS DRUG DISCOVERY

Bacterial Carbonic Anhydrases as Drug Targets: Toward Novel Antibiotics?

(2011) Claudiu T. Supuran   Frontiers in Pharmacology

Carbonic anhydrase inhibitors

(2010) Claudiu T. Supuran   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides

(2010) Fabio Pacchiano et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents

(2010) Jean-Yves Winum et al.   CURRENT PHARMACEUTICAL DESIGN

The β-Carbonic Anhydrases from Mycobacterium tuberculosis as Drug Targets

(2010) Isao Nishimoria et al.   CURRENT PHARMACEUTICAL DESIGN

Overview perspective of bacterial resistance

(2010) Guilherme H Furtado et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms

(2010) Claudiu T. Supuran   MOLECULAR DIVERSITY

Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c

(2009) Fabrizio Carta et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Carbonic Anhydrase Inhibitors. Cloning, Characterization, and Inhibition Studies of a New β-Carbonic Anhydrase fromMycobacterium tuberculosis

(2009) Isao Nishimori et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular Cloning, Characterization, and Inhibition Studies of the Rv1284 β-Carbonic Anhydrase fromMycobacterium tuberculosiswith Sulfonamides and a Sulfamate

(2009) Tomoko Minakuchi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Low Nanomolar and Subnanomolar Inhibitors of the Mycobacterial β-Carbonic Anhydrases Rv1284 and Rv3273

(2009) Özlen Güzel et al.   JOURNAL OF MEDICINAL CHEMISTRY

The α and β Classes Carbonic Anhydrases from Helicobacter pylori as Novel Drug Targets

(2008) Hiroaki Takeuchi et al.   CURRENT PHARMACEUTICAL DESIGN

Structure and Inhibition of the CO2-Sensing Carbonic Anhydrase Can2 from the Pathogenic Fungus Cryptococcus neoformans

(2008) Christine Schlicker et al.   JOURNAL OF MOLECULAR BIOLOGY

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

(2008) Claudiu T. Supuran   NATURE REVIEWS DRUG DISCOVERY

Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis

(2008) Christopher Dye   NATURE REVIEWS MICROBIOLOGY

Emerging Drugs for Active Tuberculosis

(2008) Ann Ginsberg   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment

(2008) H.D. Hollis Showalter et al.   TUBERCULOSIS

Recent advances in antituberculous drug development and novel drug targets

(2008) Haruaki Tomioka et al.   Expert Review of Respiratory Medicine